Optimization of current and future therapy for autoimmune diseases

Nature Medicine

Volumn 18, Issue 1, 2012, Pages 59-65

  Steinman, Lawrence ^a   Merrill, Joan T ^b   McInnes, Iain B ^c   Peakman, Mark ^d,e  

^a STANFORD UNIVERSITY   (United States)

^b UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

^d KING'S COLLEGE LONDON   (United Kingdom)

^e NONE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ALEMTUZUMAB; AQUAPORIN 4; AUTOANTIGEN; BETA1 INTERFERON; BIOLOGICAL MARKER; CD20 ANTIGEN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FINGOLIMOD; GLATIRAMER; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METHOTREXATE; MYELIN BASIC PROTEIN; NATALIZUMAB; RITUXIMAB; THYROXINE; TOCILIZUMAB; TOPIRAMATE; VASCULAR CELL ADHESION MOLECULE 1;

ADAPTIVE IMMUNITY; ALLERGIC ENCEPHALOMYELITIS; AUTOIMMUNE DISEASE; COMBINATION CHEMOTHERAPY; COMORBIDITY; DISEASE ACTIVITY; ENTERITIS; GRAVES DISEASE; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; MONOTHERAPY; MULTIPLE SCLEROSIS; MYASTHENIA GRAVIS; NONHUMAN; PRIORITY JOURNAL; RELAPSING REMITTING MULTIPLE SCLEROSIS; REVIEW; RHEUMATOID ARTHRITIS; TREATMENT RESPONSE;

ANTIGENS; AUTOIMMUNE DISEASES; BIOMARKERS, PHARMACOLOGICAL; DRUG COMBINATIONS; HUMANS; INTERFERON-BETA; MOLECULAR TARGETED THERAPY; SIGNAL TRANSDUCTION; TRANSLATIONAL MEDICAL RESEARCH; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84855522136     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.2625     Document Type: Review

References (94)

1. Feldmann, M. Annu. Rev. Immunol. 27, 1-27 (2009).
2. Feldmann, M. & Steinman, L. Nature 435, 612-619 (2005).
3. Dörner, T., Radbruch, A. & Burmester, G.R. Nat. Rev. Rheumatol. 5, 433-441 (2009).
4. Hueber, W. et al. Arthritis Res. Ther. 11, R76 (2009).
5. Lee, L.F. et al. Sci. Transl. Med. 3, 93ra68 (2011).
6. Grigor, C. et al. Lancet 364, 263-269 (2004).
7. Goekoop-Ruiterman, Y.P. et al. Arthritis Rheum. 52, 3381-3390 (2005).
8. Dunoyer, M. Nat. Rev. Drug Discov. 10, 475-476 (2011).
9. Peakman, M. & von Herrath, M. Diabetes 59, 2087-2093 (2010).
10. Hayday, A.C. & Peakman, M. Nat. Immunol. 9, 575-580 (2008).
11. Steinman, L. Sci. Am. 269, 106-114 (1993).
12. Grozinsky-Glasberg, S., Fraser, A., Nahshoni, E., Weizman, A. & Leibovici, L. J. Clin. Endocrinol. Metab. 91, 2592-2599 (2006).
13. Laurberg, P. et al. Eur. J. Endocrinol. 158, 69-75 (2008).
14. McFarland, H.F. & Martin, R. Nat. Immunol. 8, 913-919 (2007).
15. Arnon, R. & Sela, M. Mol Recognit. 16, 412-421 (2003).
16. Kappos, L. et al. N. Engl. J. Med. 362, 387-401 (2010).
17. CAMMS223 Trial Investigators. N. Engl. J. Med. 359, 1786-1801 (2008).
18. Kappos, L. et al. Lancet 372, 1463-1472 (2008).
19. O'Connor, P.W. et al. Neurology 66, 894-900 (2006).
20. Comi, G. et al. Mult. Scler. 16, 1360-1366 (2010).
21. Polman, C.H. et al. N. Engl. J. Med. 354, 899-910 (2006).
22. Steinman, L. Nat. Rev. Drug Discov. 4, 510-518 (2005).
23. Genovese, M.C. et al. N. Engl. J. Med. 353, 1114-1123 (2005).
24. Genovese, M.C. et al. Arthritis Rheum. 58, 2968-2980 (2008).
25. Steinman, L. Nat. Immunol. 11, 41-44 (2010).
26. Griffiths, C.E. et al.; ACCEPT Study Group. N. Engl. J. Med. 362, 118-128 (2010).
27. Strober, B.E., Crowley, J.J., Yamauchi, P.S., Olds, M. & Williams, D.A. Br. J. Dermatol. 165, 661-668 (2011).
28. Internantional MS Genetics Consortium and Wellcome Trust Case Control Consortium et al. Nature 476, 214-219 (2011).
29. Steinman, L. Nat. Rev. Immunol. 9, 440-447 (2009).
30. Arnett, H.A. et al. Nat. Neurosci. 4, 1116-1122 (2001).
31. Axtell, R.C., de Jong, B.A. & Boniface, K. Nat. Med. 16, 406-412 (2010).
32. van Holten, J. et al. Arthritis Res. Ther. 6, R239-R249 (2004).
33. http://www.biogenidec.com/press-release-details. aspx?ID=5981&ReqId= 1576802
34. Gorelik, L. et al. Ann. Neurol. 68, 295-303 (2010).
35. Jones, J.L. et al. J. Clin. Invest. 119, 2052-2061 (2009).
36. Hueber, W., Utz, P.J., Steinman, L. & Robinson, W.H. Arthritis Res. 4, 290-295 (2002).
37. Robinson, W.H. et al. Nat. Med. 8, 295-301 (2002).
38. Hueber, W. et al. Arthritis Res. Ther. 11, R76 (2009).
39. Owczarczyk, K. et al. Sci. Transl. Med. 3, 101ra92 (2011).
40. Ishizu, T. et al. Brain 128, 988-1002 (2005).
41. Warabi, Y., Matsumoto, Y. & Hayashi, H. J. Neurol. Sci. 252, 57-61 (2007).
42. Shimizu, Y. et al. J. Neurol. 255, 305-307 (2008).
43. Palace, J., Leite, M.I., Nairne, A. & Vincent, A. Arch. Neurol. 67, 1016-1017 (2010).
44. Mannon, P.J. et al. Gut 60, 449-455 (2011).
45. Merrill, J.T. et al. Arthritis Rheum. 62, 222-233 (2010).
46. Merrill, J. et al. Lupus 20, 709-716 (2011).
47. Risch, N. & Zhang, H. Science 268, 1584-1589 (1995).
48. Dudley, J.T. et al. Sci. Transl. Med. 3, 96ra76 (2011).
49. Bhat, R. et al. Proc. Natl. Acad. Sci. USA 107, 2580-2585 (2010).
50. Platten, M. et al. Proc. Natl. Acad. Sci. USA 106, 14948-14953 (2009).
51. Stegbauer, J. et al. Proc. Natl. Acad. Sci. USA 106, 14942-14947 (2009).
52. Sattar, N. & McInnes, I.B. Curr. Opin. Rheumatol. 17, 286-292 (2005).
53. Dunn, S.E. J. Exp. Med. 203, 401-412 (2006).
54. Lozanoska-Ochser, B., Barone, F., Pitzalis, C. & Peakman, M. Diabetes 55, 1004-1010 (2006).
55. Graham, K.L. et al. Arthritis Rheum. 58, 2098-2104 (2008).
56. Wagner, J.A. et al. Clin. Pharmacol. Ther. 87, 539-542 (2010).
57. Kagan, J.M., Gupta, N., Varghese, S. & Virkar, H. J. Am. Med. Inform. Assoc. published online, doi:10.1136/amiajnl-2011-000114 (4 August 2011).
58. Sthoeger, Z.M. et al. J. Autoimmun. 33, 77-82 (2009).
59. Wallace, D.J. & Tumlin, J.A. Lupus 13, 323-327 (2004).
60. Muller, S. et al. Arthritis Rheum. 58, 3873-3883 (2008).
61. Toyka, K.V. et al. N. Engl. J. Med. 296, 125-131 (1977).
62. Osserman, K.E. & Teng, P. J. Mt. Sinai Hosp. N.Y. 23, 711-727 (1956).
63. Mantegazza, R., Bonanno, S., Camera, G. & Antozzi, C. Neuropsychiatr. Dis. Treat. 7, 151-160 (2011).
64. Illa, I. et al. J. Neuroimmunol. 201, 90-94 (2008).
65. Lennon, V.A., Kryzer, T.J., Pittock, S.J., Verkman, A.S. & Hinson, S.R. J. Exp. Med. 202, 473-477 (2005).
66. Hinson, S.R., McKeon, A., Fryer, J.P. & Apiwattanakul, M. Arch. Neurol. 66, 1164-1167 (2009).
67. Crane, J.M. et al. J. Biol. Chem. 286, 16516-16524 (2011).
68. Tradtrantip, L. et al. Ann. Neurol. (in the press).
69. Steinman, L. & Zamvil, S. Ann. Neurol. (in the press).
70. Stanley, J.R. & Amagai, M. N. Engl. J. Med. 355, 1800-1810 (2006).
71. Eisenbarth, G.S. et al. Autoimmun. Rev. 1, 139-145 (2002).
72. Michels, A.W. & Eisenbarth, G.S. Semin. Immunol. 23, 214-219 (2011).
73. Raz, I. et al. Lancet 358, 1749-1753 (2001).
74. Wherrett, D.K. et al. Lancet 378, 319-327 (2011).
75. Eisenbarth, S.C., Colegio, O.R., O'Connor, W., Sutterwala, F.S. & Flavell, R.A. Nature 453, 1122-1126 (2008).
76. Steinman, L. J. Intern. Med. 267, 441-451 (2010).
77. Solvason, N. et al. J. Immunol. 181, 8298-8307 (2008).
78. Vehik, K. et al. Diabetes Care 34, 1585-1590 (2011).
79. Peakman, M. & von Herrath, M. Diabetes 59, 2087-2093 (2010).
80. Thrower, S.L. et al. Clin. Exp. Immunol. 155, 156-165 (2009).
81. Fourlanos, S. et al. Diabetes 60, 1237-1245 (2011).
82. http://www.thepharmaletter.com/file/109053/andromedas-type-1-diabetes- candidate-diapep277-meetsph-iii-primary-endpoint.html
83. Dolgin, E. Nat. Med. 16, 740-743 (2010).
84. Sabatos-Peyton, C.A., Verhagen, J. & Wraith, D.C. Curr. Opin. Immunol. 22, 609-615 (2010).
85. Getts, D.R. et al. J. Immunol. 187, 2405-2417 (2011).
86. Lutterotti, A., Sospedra, M. & Martin, R. J. Neurol. Sci. 274, 18-22 (2008).
87. Garren, H. et al. Ann. Neurol. 63, 611-620 (2008).
88. Bar-Or, A. et al. Arch. Neurol. 64, 1407-1415 (2007).
89. Campbell, J.D. et al. J. Exp. Med. 206, 1535-1547 (2009).
90. Velthuis, J.H. et al. Diabetes 59, 1721-1730 (2010).
91. van Vollenhoven, R.F. et al. Ann. Rheum. Dis. 69, 74 (2010).
92. Navarra, S.V. et al. Lancet 377, 721-731 (2011).
93. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm246489.htm
94. Matthews, J.B. et al. Clin. Exp. Immunol. 160, 176-184 (2010).